.png)
SummarySince 12 January 2025 a new medicine for cancer or an advanced therapy reaching the European market is assessed clinically once, jointly, for the whole European Union. The joint clinical assessment does not set a price and does not decide reimbursement. It changes the evidence that every national pricing decision starts from, which is why it belongs in a pricing conversation rather than only in a regulatory one.
The European framework for health technology assessment establishes a scientific analysis of clinical evidence on the relative effects of a health technology, a medicine or a medical device, on health outcomes. The assessments are carried out by the member states together, with an assessor and a co-assessor appointed for each evaluation, and they support national processes rather than replacing them.
The European Commission's page on joint clinical assessments states the boundary plainly: the output is a scientific analysis that supports national health technology assessment processes. Pricing and reimbursement stay with the member states.
That boundary is the single most important thing to understand about the regulation. It centralises the clinical evidence assessment and leaves the value judgement, the price and the reimbursement decision exactly where they were.
The regulation applies in phases, by product category.
| From | In scope |
|---|---|
| 12 January 2025 | New cancer medicines and advanced therapy medicinal products |
| 2026 | Selected high risk medical devices |
| 13 January 2028 | Orphan medicines |
| 13 January 2030 | All centrally authorised medicines |
For anyone planning European launches, those dates are planning constraints rather than background. A product entering the oncology or advanced therapy space today is already inside the system. An orphan product in development will meet it, and a centrally authorised product of any kind will meet it by the end of the decade.
The most concrete change is the timing of the submission. For products in scope, the developer submitting a marketing authorisation application to the European Medicines Agency also submits the relevant documentation to the health technology assessment secretariat, including the summary of product characteristics and the clinical overview.
That single sentence reorders a lot of work. Evidence that was previously assembled per country, at different times, in response to different national requirements, now has to be ready earlier and in one place.
Three practical consequences follow:
The framework distributes work across three layers, and confusing them is the most common misreading.
The European Medicines Agency decides whether a medicine may be placed on the market. That is authorisation, and it is unchanged.
The joint clinical assessment analyses the relative clinical effects, carried out by member states together through an assessor and a co-assessor.
The national authorities decide whether and at what price a product is reimbursed, using the joint analysis as one input among several.
Read as a sequence, the regulation inserts a shared step between authorisation and national appraisal. It does not merge any two of those three layers, and nothing in it obliges a member state to reach the same conclusion as its neighbour.
A clinical assessment establishes what a technology does relative to a comparator: how much better, on which outcome, with what certainty.
A value judgement decides what that is worth to a given health system, at a given budget, for a given population. Two countries can accept the same clinical finding and still reach different prices, because they answer the second question differently.
That distinction is why a shared clinical assessment does not produce a shared price, and it is also why the most contested part of any national appraisal tends to survive the joint step. Choice of comparator, relevance of an outcome and acceptable uncertainty sit at the boundary between the two questions, which is exactly where national appraisals argue.
The regulation does not touch price setting. It still affects prices through three channels.
The clinical basis is shared. Where national assessments previously reached different conclusions partly because they read different evidence syntheses, they now start from a common scientific analysis. The remaining differences are value judgements and budget constraints, which are the things that should differ.
The timing shifts. A joint assessment available at or near authorisation compresses the interval before national appraisal can begin. Whether that shortens access in practice depends on national capacity, not on the regulation.
The comparator matters more. In systems where a price is negotiated against a demonstrated additional benefit, and the German procedure is the clearest example, the choice of comparator largely determines the outcome. A European assessment that settles comparators for the clinical question narrows the space in which a national comparator choice can be argued.
Every national mechanism described elsewhere in our work continues unchanged.
Germany keeps its benefit assessment and its negotiation of a reimbursement amount, and the outcome remains visible in the price data. We cover that in our article on pharmaceutical market access in Germany.
External reference pricing continues to read published prices in other countries, and remains list price based.
Internal reference systems, such as the German fixed reimbursement amount, continue to group therapeutically comparable products domestically.
Managed entry agreements and confidential rebates continue to sit below the published level, which is where the difference between a list price and a paid price lives.
In other words: the regulation changes the input to national decisions, not the decisions and not the data that those decisions produce.
It does not produce a European price. It does not produce a European reimbursement decision. It does not perform an economic evaluation: the joint work is a clinical assessment, and cost effectiveness, budget impact and willingness to pay remain national.
It also does not remove national evidence requirements. A member state can still ask for analyses that the joint assessment did not cover, which is why the workload for a developer changes shape rather than simply shrinking.
That it creates a European price. It does not. Prices and reimbursement remain national competences, and the regulation says so.
That it replaces national assessment. It supports national processes. Member states continue to run their own appraisals and can require additional analyses.
That it removes the need for country level pricing data. The opposite is closer to the truth. With the clinical basis converging, the remaining variance between countries sits in price, reimbursement status and mechanism, which is precisely what national price data describes.
For a market access or pricing team the practical preparation is less about the regulation's text and more about being able to answer national questions quickly once the joint assessment lands.
Medicines dominate the discussion, but the framework also reaches selected high risk medical devices from 2026. The device sector enters with a different evidence culture, fewer centralised processes and national assessment traditions that vary more widely than in pharmaceuticals.
For anyone whose portfolio spans both, that is worth planning separately rather than as an extension of the medicines timetable.
The joint clinical assessment centralises the clinical evidence and leaves everything commercial where it was. Since 12 January 2025 it applies to new cancer medicines and advanced therapies, reaching orphan products in January 2028 and all centrally authorised medicines in January 2030. For pricing teams the effect is indirect and real: the same clinical analysis now feeds national decisions that still differ in value judgement, budget and mechanism, and the published price data those decisions produce continues to behave exactly as before.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus external reference pricing in Europe.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
